Photo by martindorsch from unsplash
Secukinumab, a fully human monoclonal antibody that selectively neutralizes interleukin‐17A, a cornerstone cytokine in psoriasis, has shown long‐lasting efficacy and safety in the complete spectrum of psoriasis manifestations. Click to show full abstract
Secukinumab, a fully human monoclonal antibody that selectively neutralizes interleukin‐17A, a cornerstone cytokine in psoriasis, has shown long‐lasting efficacy and safety in the complete spectrum of psoriasis manifestations.
Keywords:
shows high;
efficacy;
high sustained;
secukinumab shows;
psoriasis;
secukinumab
Journal Title: British Journal of Dermatology
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: British Journal of Dermatology
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!